Research Grants and 7 Development Awards for Fellowship Trainees Will Fund Critical Research Across Multiple Neuromuscular ...

VectorY Therapeutics appoints Jim Scibetta as CEO to lead development of VTx-002, a vectorized antibody therapy targeting TDP ...

If you receive a denial letter from your insurer, don’t appeal the decision before seeking legal advice, says a leading ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA ...

The delay in diagnosing ALS means treatment and supportive care is received later, which can have a significant impact on ...

Shelby Kinsey lives with a rare, fast-progressing form of ALS — but she has to spend her precious time fighting for insurance ...

Troy Pruett, a Grapevine resident, will be competing in his 96th marathon this weekend and getting one step closer to the ...

In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...

The Centers for Medicare & Medicaid Services (CMS) has mandated Medicare Advantage insurers to provide coverage for Biogen's amyotrophic lateral sclerosis (ALS) medication, Qalsody. This directive ...

Receiving a terminal diagnosis is one of life’s most profoundly difficult moments — a collision of disbelief, fear, and ...